Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

CAP TODAY

Verichem enzyme calibration verifiers for liver function testing

October 2023—Verichem Laboratories offers multilevel enzyme calibration verification materials for liver function testing as part of its liquid-stable Enzyme ER Verifier kit. The kit contains the enzymes alanine aminotransferase (ALT/SGPT), alkaline phosphatase (AP/ALP), aspartate aminotransferase (AST/SGOT), gamma-glutamyl transferase (GGT/GGTP), lactate dehydrogenase (LD/LDH), amylase, cholinesterase, creatine phosphokinase, and lipase. Its proprietary formulation is designed to include at least one concentration for each enzyme within the normal range. The verifiers are intended to be treated as patient specimens and are compatible with wet chemistry systems from Abbott, Beckman Coulter, Roche, and Siemens Healthineers. Shelf life is 18 months.

FDA clears Alinity h-series hematology system

October 2023—Abbott has received FDA clearance for its Alinity h-series hematology system, which includes the Alinity hq, an automated hematology analyzer, and Alinity hs, an integrated slide maker and stainer. The Alinity hq leverages multiangle polarized scatter separation (MAPPS) technology, which uses light scattering to distinguish cellular features and identify various blood cells, and processes up to 119 CBC results per hour. The system can be integrated into an existing core lab operation.

Visiopharm, Boston Cell Standards to develop IHC technology

October 2023—Visiopharm and Boston Cell Standards announced they are partnering to integrate immunohistochemistry calibration standards with image analysis software for quality assurance. The joint technology solution will enable laboratories to meet key provisions of regulatory changes proposed in an editorial published in Archives of Pathology & Laboratory Medicine.

Illumina, Pillar Biosciences announce partnership

September 2023—Illumina and Pillar Biosciences announced a strategic partnership to make Pillar’s suite of oncology assays commercially available worldwide as part of Illumina’s portfolio of oncology products. The companies say the agreement will result in an unprecedented offering of complementary next-generation sequencing solutions that will enhance the efficiency, accuracy, and cost-effectiveness of oncology testing through advanced sequencing techniques.

Comanche drug for preeclampsia gets fast track designation

September 2023—Comanche Biopharma announced it has received fast track designation from the FDA for its CBP-4888 as a novel small interfering ribonucleic acid (siRNA) therapy for preeclampsia. CBP-4888 is a fixed-dose combination of two chemically synthesized, lipid-conjugated siRNA duplex oligonucleotides, siRNA-2283 and siRNA-2519, targeting two soluble fms-like tyrosine kinase–1 (sFLT1) mRNA isoforms. Fast track is designed to facilitate the development and expedite the review process of drugs to treat serious conditions and fill an unmet medical need.

New book in Foundations in Diagnostic Pathology series

September 2023—Differential Diagnoses in Surgical Pathology: Tumors and their Mimickers, a new volume in the Foundations in Diagnostic Pathology series, has been published by Elsevier. The book, by Fadi W. Abdul Karim, MD, MEd, and Charles Sturgis, MD, aims to help readers quickly differentiate entities that have similar, overlapping histopathologic features and guide them through the decision-making process, providing a road map to the main differential diagnostic considerations that must be addressed when formulating a diagnosis. The book includes high-quality illustrations of similar-looking but distinct entities for side-by-side comparison in a user-friendly format with at-a-glance boxes and tables throughout the text, as well as selected references for further study. An enhanced ebook version is included with purchase.

GADx reintroduces IT-Leish test for visceral leishmaniasis

September 2023—Global Access Diagnostics announced the launch of IT-Leish, a UKCA-marked rapid test used for diagnosing visceral leishmaniasis. The company acquired the manufacturing rights for IT-Leish from Bio-Rad in September 2022 to prevent the test’s withdrawal from the market and support the World Health Organization’s strategic plan to eliminate life-threatening neglected tropical diseases.

KSL Diagnostics opens transplant immunology laboratory

September 2023—KSL Diagnostics, Buffalo, NY, has opened a transplant immunology laboratory to serve the western New York region. KSL is the provider for Erie County Medical Center and Kaleida Health. ConnectLife, a community blood bank and federally designated not-for-profit organ procurement organization, uses KSL’s new lab and services Allegany, Cattaraugus, Chautauqua, Erie, Genesee, Niagara, Orleans, and Wyoming counties.

Owen Mumford introduces Unistik venous blood collection devices

September 2023—Owen Mumford has introduced its Uni­stik venous blood collection devices. Uni­stik VacuFlip features a safety guard that flips over to cover the needle after it is withdrawn from the patient’s arm. An audible click signals the safety guard is in place and the needle is locked. VacuFlip is available in three needle gauges and needle lengths.

MARKETPLACE

TRENDING